Literature DB >> 16631476

Molecular cytogenetic characterization of four previously established and two newly established Ewing sarcoma cell lines.

Károly Szuhai1, Marije Ijszenga, Hans J Tanke, Carla Rosenberg, Pancras C W Hogendoorn.   

Abstract

Most Ewing family tumors are identified by the characteristic translocation t(11;22)(q24;q12), resulting in a fusion protein EWS/FLI1 that acts as an aberrant transcription factor. In a minority of cases, the EWS gene is fused to another member of the ETS gene (ERG, ETV1, E1AF, and FEV). Though the oncogenic transforming capability of the EWS/FLI1 protein is highly suggestive, the exact pathway behind remains to be elucidated. The availability of cell lines may help in the understanding of underlying cellular processes. In this study, we have established two new Ewing sarcoma cell lines and characterized them with molecular cytogenetic tools. This technology was also applied on four other previously published Ewing sarcoma cell lines. Our findings in relation to previous data on similar tumors are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16631476     DOI: 10.1016/j.cancergencyto.2005.11.006

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  13 in total

1.  Ewing sarcoma with ERG gene rearrangements: A molecular study focusing on the prevalence of FUS-ERG and common pitfalls in detecting EWSR1-ERG fusions by FISH.

Authors:  Sonja Chen; Kemal Deniz; Yun-Shao Sung; Lei Zhang; Sarah Dry; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2015-12-22       Impact factor: 5.006

Review 2.  Soft tissue tumors associated with EWSR1 translocation.

Authors:  Salvatore Romeo; Angelo P Dei Tos
Journal:  Virchows Arch       Date:  2010-02       Impact factor: 4.064

3.  WNT5A is regulated by PAX2 and may be involved in blastemal predominant Wilms tumorigenesis.

Authors:  Yahya Tamimi; Usukuma Ekuere; Nicholas Laughton; Paul Grundy
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

4.  EWS/FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model.

Authors:  Iranzu González; Silvestre Vicent; Enrique de Alava; Fernando Lecanda
Journal:  J Mol Med (Berl)       Date:  2007-04-24       Impact factor: 4.599

5.  Evaluation of high-resolution microarray platforms for genomic profiling of bone tumours.

Authors:  Stine H Kresse; Karoly Szuhai; Ana H Barragan-Polania; Halfdan Rydbeck; Anne-Marie Cleton-Jansen; Ola Myklebost; Leonardo A Meza-Zepeda
Journal:  BMC Res Notes       Date:  2010-08-08

6.  Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells.

Authors:  Emilie P Buddingh; Marco W Schilham; S Eriaty N Ruslan; Dagmar Berghuis; Karoly Szuhai; Jolien Suurmond; Antonie H M Taminiau; Hans Gelderblom; R Maarten Egeler; Massimo Serra; Pancras C W Hogendoorn; Arjan C Lankester
Journal:  Cancer Immunol Immunother       Date:  2011-01-15       Impact factor: 6.968

7.  Tissue microarrays: applications in study of p16 and p53 alterations in Ewing's cell lines.

Authors:  Rosa Noguera; Isidro Machado; Marta Piqueras; Jose Antonio Lopez-Guerrero; Samuel Navarro; Empar Mayordomo; Antonio Pellin; Antonio Llombart-Bosch
Journal:  Diagn Pathol       Date:  2008-07-15       Impact factor: 2.644

8.  Fluorescent CXCR4 targeting peptide as alternative for antibody staining in Ewing sarcoma.

Authors:  Laurens G L Sand; Tessa Buckle; Fijs W B van Leeuwen; Willem E Corver; Alwine B Kruisselbrink; Aart G Jochemsen; Pancras C W Hogendoorn; Károly Szuhai
Journal:  BMC Cancer       Date:  2017-05-26       Impact factor: 4.430

Review 9.  Molecular pathology of sarcomas: concepts and clinical implications.

Authors:  Judith V M G Bovée; Pancras C W Hogendoorn
Journal:  Virchows Arch       Date:  2009-09-29       Impact factor: 4.064

10.  Expression of CCL21 in Ewing sarcoma shows an inverse correlation with metastases and is a candidate target for immunotherapy.

Authors:  Laurens G L Sand; Dagmar Berghuis; Karoly Szuhai; Pancras C W Hogendoorn
Journal:  Cancer Immunol Immunother       Date:  2016-07-01       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.